Showing: 1 - 3 of 3 RESULTS

Jennifer Kocour Named Chief Operating Officer of CCT Research as Company Continues U.S. Expansion

An experienced clinical research leader, Kocour will oversee business operations and strategic growth for the CCT Network of Sites

CCT Research, a company offering an innovative approach to conducting clinical trials for the prevention and treatment of debilitating diseases, announced today that Jennifer Kocour has joined the company as its Chief Operating Officer. Kocour brings a wealth of industry experience, having started her career as a Clinical Research Assistant before advancing to roles as a Site Coordinator, Regional Manager, Clinical Team Lead, and Vice President of Operations.

Kocour’s appointment comes as CCT Research continues to rapidly expand its geographic and therapeutic reach since opening its doors in 2017. “I’m excited to join a company that’s dedicated to industry innovation, exceptional patient care, and the growth and development of our staff as we continue to grow as a company,” said Kocour.

CCT Research currently has 17 sites across Arizona, Nebraska, and Utah. The sites are located in physicians’ offices, medical clinics, and senior living communities; and the company is looking to add partner sites in new markets. By embedding its clinical research infrastructure and staff into these facilities, CCT Research provides convenient and comfortable study locations for qualified patients in a variety of therapeutic areas. Recently, the company was selected to partner with several top pharmaceutical companies to conduct trials for a COVID-19 vaccine.

“Strong leadership is key to supporting these critical study efforts and future medical research,” said CJ Anderson, President of CCT Research. “Jennifer is a proven leader, and her diverse background provides an understanding of each individual’s role in conducting a successful clinical trial. We’re happy to have her as the newest member of our executive leadership team.”

About CCT Research

CCT Research is a company offering an innovative approach to conducting clinical trials for the prevention and treatment of debilitating diseases. CCT’s research sites are located within physicians’ offices, medical clinics, and senior living communities to support research in the fields of Neurology, Family Practice, and Dermatology, with plans to include additional therapy areas in the near future. The company’s unique model simplifies the process for trial participants and provides pharmaceutical sponsors with high quality data. For more information, visit cctresearch.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005945/en/

Contacts

CJ Anderson, President
CCT Research
480-702-3501
[email protected]

Source Article

Proscia Appoints Dr. Monica Santamaria-Fries as Digital Transformation Officer to Guide Laboratories Amid Surge in Digital Pathology Adoption

Former Chief of Pathology at Kaiser Permanente brings 30+ years of pathology and laboratory management experience to company’s executive team

Proscia®, a leading provider of digital and computational pathology solutions, has named pathology and laboratory management veteran Dr. Monica Santamaria-Fries to its executive team. In her role as Digital Transformation Officer, Dr. Santamaria-Fries will draw on her experience to guide diagnostic laboratories in the transition to digital pathology amid a rising demand for adoption.

Dr. Santamaria-Fries joins Proscia following a 30+ year career with The Permanente Medical Group (TPMG), which serves more than 4.5 million patients in Northern California. She was the Chief of Pathology at the Kaiser Foundation Hospital in Santa Clara, CA, where she supervised clinical and business operations for over 15 years. In addition to working as a practicing pathologist, Dr. Santamaria-Fries held appointments as Clinical Laboratory Director and, most recently, as Assistant Chair for the Regional TPMG Pathology Department, guiding strategy and operations for a group of over 125 pathologists geographically distributed across 20 facilities in Northern California.

At Proscia, Dr. Santamaria-Fries will act as the change agent for diagnostic laboratories making the transformation to digital pathology, ensuring that they are prepared to rapidly capitalize on its growing potential with an approach that evolves with their needs. She will play a critical role in all stages of the digital journey, from strategy and requirements definition through implementation. In addition, Dr. Santamaria-Fries will work closely with Proscia’s commercial, regulatory, scientific, and technology teams to shape the company’s product roadmap and communicate clinical evidence.

“We are very excited to welcome Dr. Santamaria-Fries to our leadership team,” said David West, Proscia’s CEO. “Her extensive pathology and laboratory management expertise combined with a deep appreciation of digital and computational pathology will help Proscia to continue its strong growth in the clinical market and enable us to meet the expectations of our customers as we drive further adoption.”

Adoption of digital pathology among hospital networks and diagnostics laboratories is undergoing rapid growth, especially in the face of the COVID-19 pandemic. The current standard of care for diagnosing cancer centers around pathologists and microscopes in physical laboratory spaces. Catalyzed by the global health emergency, healthcare is seeing the adoption of new technologies as telemedicine and digital approaches become the new norm. Digital pathology, which captures high resolution images of specimen, enables remote case review as well as the application of AI to help overcome the manual and subjective nature of traditional pathology.

“As a passionate pathologist and laboratorian, I am excited to help Proscia transform diagnostic medicine,” said Dr. Monica Santamaria-Fries. “Digital pathology adoption has never been more critical than it is today. I look forward to playing a key role in pushing the industry forward to increasingly drive impactful clinical and operational benefits for leading laboratories around the world.”

The addition of Dr. Santamaria-Fries is Proscia’s latest announcement in its continued quest to accelerate digital pathology adoption in clinical practice. In April, the company announced that its

Carroll Couny passes COVID-19 milestone; health officer concurs with Trump tweet, stresses social responsibility

On the same day President Trump issued a tweet that said, in part, “Don’t be afraid of Covid,” Carroll County passed a milestone with more than 2,000 total cases of COVID-19 reported.

The 22 new cases announced by the Carroll County Health Department brought the county’s overall number to 2,007. That represents nearly 1.2% of Carroll’s population, a rate that is roughly half the national average. Additionally, 147 Carroll countians have died of the disease caused by the novel coronavirus.

Trump, diagnosed with COVID-19 last week, tweeted Monday afternoon, in announcing he would soon be leaving the hospital and returning to the White House, “Feeling really good! Don’t be afraid of Covid. Don’t let it dominate your life.”

County Health Officer Ed Singer concurred with the theme of Trump’s message, while emphasizing that everyone has a “social responsibility” to help prevent the spread of COVID-19.

“I would agree with the point that Donald Trump makes in that we should not be afraid and let COVID-19 dominate our lives; however, we continue to have a responsibility to protect each other from a potentially deadly virus that has killed over 209,000 Americans,” Singer wrote in an email to the Times in response to a question about the president’s tweet. “Although some people are able to recover from this disease, many people suffer serious complications, are hospitalized, and some people die.

“We have a social responsibility to each other to take common sense steps to avoid getting others sick. Continuing to follow distancing requirements, wearing masks over our mouths and noses, avoiding large gatherings, and washing our hands are critical to doing our part to limit the spread of COVID-19 in our community.”

Of the 22 cases announced Monday, 11 of them were reported before the end of Saturday. The preliminary total of community cases for last week was 58. That was up from 44 the previous week and 54 the week before that.

The county is approaching Carroll County Public Schools’ planned date of Oct. 19 to switch to a partly in-person model. Singer and CCPS officials have said they would like to see Carroll in the “moderate” risk of COVID-19 transmission before reopening schools. That would mean a a weekly rate of 42 cases, based on U.S. Centers for Disease Control and Prevention recommendations, and would include cases originating from congregate living facilities, though only six such cases have been reported for September. Carroll has been under 42 community cases in only two of the past 12 weeks. Carroll’s current seven-day rolling positive rate is 2.10.

While Carroll saw an uptick in cases last week, McDaniel College announced Monday morning that it was reducing its COVID-19 alert level after going a week without a case. McDaniel, which has had 15 positive results out of 2,018 total tests of its campus population since Aug. 14, had moved to Yellow level last Monday, Sept. 28, after four positive tests, but has seen none since and is back to Green.

“We are